Skip to main content
. 2006 Jul;80(13):6697–6701. doi: 10.1128/JVI.02388-05

FIG. 2.

FIG. 2.

The B19 HLA-A24 FYTPLADQF tetramer-specific T-cell response in patient O1 predominantly uses TCR gene segment BV5.1. PBMC from patient O1 (2 months after symptom development) were stained with tetramer and BV monoclonal antibodies. Percentages shown are percentages of tetramer-positive PBMC.